May 2014

Aduro inks agreement with Janssen Biotech for prostate cancer candidates

Friday, May 30, 2014

Aduro BioTech, a clinical-stage biotechnology company, has entered into an agreement granting Janssen Biotechan exclusive worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer based on its novel LADD immunotherapy platform. The agreement is facilitated by the Johnson & Johnson Innovation center in California. Aduro is eligible to receive up to $365 million in upfront license fees and milestone payments upon achievement of defined development, regulatory and commercialization milestones, if multiple programs advance to commercialization, as well as tiered royalties on worldwide net sales.

[Read More]

EMA welcomes publication of the Clinical Trials Regulation

Friday, May 30, 2014

The EMA welcomes the publication of the Clinical Trials Regulation in the Official Journal of the European Union (E.U.). This legislation will foster European competitiveness and innovative capacity, and facilitate swifter development of new medicines for patients. In addition to simplifying clinical trial approvals, the regulation foresees transparency on the conduct of trials in the European Economic Area, from the point of their authorization to the publication of the results of those clinical trials.

[Read More]

Cancer Treatment Centers of America names Maurie Markman president

Thursday, May 29, 2014

Cancer Treatment Centers of America (CTCA), a national network of five hospitals that specialize in the treatment of patients fighting complex or advanced-stage cancer, has appointed Maurie Markman, M.D., president of the company’s Medicine & Science unit, where he will be responsible for advancing the organization’s overall commitment to clinical excellence, innovation, safety and patient satisfaction. Markman was senior vice president of Clinical Affairs and national director of Medical Oncology at CTCA.

[Read More]

WIRB-Copernicus Group launches oncology IRB to meet challenges of cancer research

Thursday, May 29, 2014

The WIRB-Copernicus Group (WCG), a large provider of regulatory and ethical review services for clinical research, has formed WCG Oncology, a new cancer-focused institutional review board, along with the WCG Oncology Expert Advisory Board, which includes James E. Rothman, Ph.D., the 2013 recipient of the Nobel Prize in Medicine and chairman of cell biology at Yale Medical School.  

[Read More]